• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Ogunsen: Challenges persist in Q3 - ABG

OGUN BEksterne analyser22.11.2023, 07.25

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier

Download analyse (PDF)
Organic sales decline of 6% y-o-y
EBIT margin of 7.9% (13.2%)
Q4 demand on same level as Q3


Q3: Sales 6% and EBIT 7% below ABGSCe

Ogunsen's Q3 results were below our expectations, with sales of SEK 111m (-6% y-o-y), which was 6% below ABGSCe. It was lower recruitment sales in particular that explained the deviation, as these only constituted 7% (12%) of total revenues. The consultancy part was roughly unchanged y-o-y, where our expectation was for it to grow by 2% (down from 4% in Q2). The decline in sales is roughly in line with the overall market, but as Ogunsen has a high degree of exposure in Stockholm (where the market was down 17% in Q3), we assess that it gained some market share in its targeted geographical area. EBIT was SEK 8.7m (15.5m) for an EBIT margin of 7.9% (13.2%). Although this was 7% below ABGSCe, we think it is positive that the company can maintain 7-8% EBIT margins in this market environment, as it suggests that the bottom in profitability will be clearly higher than during the last challenging period in '19-'20, where it bottomed at 4%.